Suchergebnisse

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. However, when you're an income investor, your primary focus is

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is

Roche RHHBY announced that the FDA has accepted its supplemental application for Gazyva/Gazyvaro (obinutuzumab) to treat systemic lupus erythematosus (SLE), based on strong phase III ALLEGORY study

ADMA Biologics ADMA specializes in plasma-based therapies used to treat immune disorders and help prevent certain infections. Its flagship product, Asceniv, is an intravenous immunoglobulin (IVIG)

Cleveland-Cliffs Inc.’s CLF first-quarter 2026 adjusted loss was 40 cents per share, narrower than the Zacks Consensus Estimate of a loss of 44 cents. It reported an adjusted loss of 93 cents per

United Parcel Service UPS is scheduled to report its first-quarter 2026 results on April 28, 2026, before the market opens. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings per

Moderna MRNA reported that the European Commission (EC) has granted marketing authorization for mCombriax (mRNA-1083), its mRNA combination vaccine for active immunization for the prevention of

Enphase Energy, Inc. ENPH is scheduled to release its first-quarter 2026 results on April 28, after market close. In the last reported quarter, the company delivered an earnings surprise of 31.48%

Jabil (JBL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one

Ichor Holdings (ICHR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates --

US Foods (USFD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting

Fabrinet (FN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the

LendingClub (LC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to

Shares of Perma-Pipe International Holdings, Inc. PPIH have declined 12.4% since the company reported its earnings for the quarter ended Jan. 31, 2026, underperforming the S&P 500 index’s 1.1%

Merck MRK, along with its partner Eisai, announced that the phase III LITESPARK-012 study, which evaluated Keytruda-based triplet regimens for the first-line treatment of patients with advanced

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Merchants Bancorp (MBIN), which belongs

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? L3Harris (LHX), which belongs to the